- American City Business Journals•17 hours ago
Medford biotech Seventh Sense Biosystems said Thursday that the FDA has approved its push-button blood-collection device for use by healthcare professionals to monitor blood sugar. The move by the FDA allows Seventh Sense to market the device, called TAP, for monitoring blood sugar levels in diabetic and pre-diabetic patients. The privately-held, 25-employee company has billed TAP as the world's first push-button blood collection device.
- MarketWatch•20 hours ago
Companies have had better earnings growth than those in the U.S. and valuations are low, among other factors.
- Motley Fool•3 days ago
The drugmaker announced a delay to approval of its three-times-weekly version of Glatopa.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||77.07 - 77.66|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.66|
|Dividend & Yield||2.75 (3.57%)|
|1y Target Est||N/A|